Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Non-Current Assets: 2021-2024

Historic Other Non-Current Assets for Janux Therapeutics (JANX) over the last 4 years, with Dec 2024 value amounting to $2.9 million.

  • Janux Therapeutics' Other Non-Current Assets fell 6.94% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 6.94%. This contributed to the annual value of $2.9 million for FY2024, which is 14.95% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Other Non-Current Assets is $2.9 million, which was up 14.95% from $2.5 million recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Other Non-Current Assets peaked at $2.9 million during FY2024, and registered a low of $816,000 during FY2021.
  • In the last 3 years, Janux Therapeutics' Other Non-Current Assets had a median value of $2.5 million in 2023 and averaged $2.3 million.
  • Data for Janux Therapeutics' Other Non-Current Assets shows a peak YoY spiked of 80.50% (in 2023) over the last 5 years.
  • Janux Therapeutics' Other Non-Current Assets (Yearly) stood at $816,000 in 2021, then skyrocketed by 70.34% to $1.4 million in 2022, then soared by 80.50% to $2.5 million in 2023, then increased by 14.95% to $2.9 million in 2024.